Long-Term Pharmacotherapy of Obsessive-Compulsive Disorder: A Double-Blind Controlled Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The aim of this study was to investigate whether obsessive-compulsive patients previously treated successfully with clomipramine or fluvoxamine could tolerate reduction of the daily dosage without worsening of the clinical condition. Thirty informed obsessive-compulsive patients, given a diagnosis according to DSM-III-R criteria, were recruited consecutively into the study. Patients were blindly assigned to one of the groups of treatment with different rates of reduction of the previously effective daily drug dosage: group 1 (control group, no reduction), group 2 (reduction of 33-40%), and group 3 (reduction of 60-66%). The entire study lasted 102 days. From baseline to the end of the study, the clinical condition was evaluated by the administration of standardized tests (Yale-Brown Obsessive-Compulsive Scale, Hamilton Rating Scale for Depression, Clinical Global Impression [CGI] scale), and blood samples were collected for plasma drug level determinations. The criterion for discontinuation of the study was the worsening of obsessive-compulsive symptoms, arbitrarily defined by an increase of > 5% from the baseline total Yale-Brown Obsessive-Compulsive Scale score, as measured in two successive assessments, and a worsening of global clinical condition as measured by the CGI scale. The main result of the study was borne out from the survival analysis. There were no significant differences in the cumulative proportion of patients from each group of treatment who did not worsen during the 102 days of observation. This preliminary result, which needs to be confirmed in larger samples, suggests that long-term maintenance therapy for obsessive-compulsive disorder might be provided with lower dosages of the antiobsessional drug, with clear advantages for tolerability and compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clomipramine Treatment of Obsessive-Compulsive Disorder: I. A Controlled Clinical Trial
Thorén, P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780240079009 · Cited by 497
Clomipramine Treatment of Childhood Obsessive-Compulsive Disorder: A Double-blind Controlled Study
Flament, M. F. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330057007 · Cited by 466
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.12.1521 · Cited by 301
Cited by
Eddy, K. T., Dutra, L., Bradley, R., & Westen, D. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.08.004 · Cited by 475
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Pallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408
“Maintenance and discontinuation studies (Pato et al., 1988, 1990; Leonard et al., 1991; Mundo et al., 1997) show a high rate of relapse (65–90%) after acute discontinuation of SRI treatment and a lower degree of response to the same treatment effective for the previous episode (Maina et al.”
BackgroundEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Jenike, M. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp031002 · Cited by 259
Metadata
- Authors
- Mundo, E., Bareggi, S. R., Pirola, R., Bellodi, L., & Smeraldi, E.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1997-02
- Volume
- 17
- Issue
- 1
- Pages
- 4-10
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2334756517
- Cited by
- 44
- References
- 3
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Pharmacotherapy of Obsessive-Compulsive Disorder: A Double-Blind Controlled Study. https://app.cochat.ai/papers/10.1097/00004714-199702000-00002
- The paper
- Mundo, E., Bareggi, S. R., Pirola, R., Bellodi, L., & Smeraldi, E. (1997). Long-Term Pharmacotherapy of Obsessive-Compulsive Disorder: A Double-Blind Controlled Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199702000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.